| abstract |
The present invention relates to an antiviral drug that has, as a target gene, a gene having an effect of maintaining a virus-derived nucleic acid in a host cell, and has, as an active ingredient, a substance capable of suppressing the expression of the target gene or the activity of a protein coded by the target gene, wherein the target gene is one or more genes selected from the group consisting of the DOCK11 gene, LIPG gene, DENND2A gene, and HECW2 gene. The present invention further relates to a screening method for said antiviral drug. |